Exact Sciences Reports Q2 2024 Results with Record Revenue and Adjusted EBITDA

Details

The company screened over 1 million people with Cologuard and tested a record number of cancer patients with Oncotype DX. Exact Sciences also advanced its pipeline, generating evidence for molecular residual disease, multi-cancer screening, and blood-based colorectal cancer screening tests. The company maintained its full-year 2024 revenue guidance and raised its full-year adjusted EBITDA guidance midpoint by $8 million.

Items reported

Exhibits (1)

About Exact Sciences Corp

Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.